EFGAM launches New Capital Healthcare Disruptors fund

Managed by Mike Clulow and US growth equity team

Pedro Gonçalves
clock • 1 min read

EFG Asset Management (EFGAM) has launched the New Capital Healthcare Disruptors fund to target innovative healthcare companies that are seizing market share through disruptive technologies and services.

Benchmarked against the MSCI World Health Care index, the fund will have up to 30 holdings across the market cap spectrum. It is managed by Mike Clulow and EFGAM's US growth equity team, Tim Butler, Joel Rubenstein and Chelsea Wiater, all of whom are based in Portland, Oregon. Rather than focusing on single segments of the healthcare sector, the team looks across the spectrum. This includes biopharmaceuticals, medical devices, healthcare services and pharmaceutical outsourcing. Go big or go home: Will size matter for certain sectors in 2021? Clulow said: "We search for companies...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Funds

Jupiter retains grip on star manager Ben Whitmore's Global Value Equity fund

Jupiter retains grip on star manager Ben Whitmore's Global Value Equity fund

Whitmore to exit by 1 November

Linus Uhlig
clock 24 October 2024 • 2 min read
UK funds record steepest drop in fees in the last decade

UK funds record steepest drop in fees in the last decade

Broadridge report

Sorin-Andrei Dojan
clock 22 October 2024 • 2 min read
T. Rowe Price opens $80.4bn US Structured Research Equity strategy to UK investors

T. Rowe Price opens $80.4bn US Structured Research Equity strategy to UK investors

Complements fund’s SICAV version

Sorin-Andrei Dojan
clock 22 October 2024 • 1 min read
Trustpilot